Seeking Alpha

Seeking Alpha Portfolio App for iPad

213 people get ALTH articles and Market Currents by email alert.

Get email alerts on ALTH »

ALTH

Allos Therapeutics, Inc.

6/19/2013, 5:13 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, August 29, 2012, 11:52 AM Spectrum Pharmaceuticals (SPPI +4.6%) says the FTC has cleared its acquisition of Allos Therapeutics (ALTH +1.1%). SPPI has been looking to boost its hematology franchise, and has been chasing ALTH over most of the summer in pursuit of its lymphoma drug Folotyn. The tender offer for Allos shares is slated to expire at 5pm EST on September 4, 2012. 3 Comments [Healthcare, M&A, On the Move]
Tuesday, July 17, 2012, 1:02 PM Allos (ALTH) storms 19.6% higher after Spectrum (SPPI -0.9%) provides reassurances that its $206M+ acquisition of Allos is progressing well and that the company was "very happy with everything." Allos' shares plunged 20% yesterday on rumors that the deal had fallen through. 1 Comment [On the Move, Healthcare]
Thursday, April 5, 2012, 8:52 AM Allos Therapeutics (ALTH) roars to a 27.9% gain premarket up to $1.85 a share after Spectrum Pharmaceuticals (SPPI) agrees to buy the company. The trading price falls in the range between the offering price of $1.82/share and the $1.93-a-share value of the deal with kickers. Shares of SPPI -9.9% premarket, reeling from a negative results from a trial on apaziquone. Comment! [On the Move, Healthcare, M&A]
Thursday, April 5, 2012, 8:50 AM Premarket gainers: ALTH +28%. LLEN +14%. WOLF +11%. BBBY +5%. ZLCS +4%. GFI +3%. TLK +3%.
Losers: PLCM -19%. CKEC -10%. SPPI -10%. HOV -5%. ALU -5%. VE -4%. ING -3%. STD -3%. 1 Comment
Thursday, April 5, 2012, 7:16 AM Spectrum Pharmaceuticals (SPPI) buys Allos Therapeutics (ALTH) for $1.82 a share in a deal that also includes a $0.11/share contingency if certain European regulatory approvals and milestones for Folotyn are hit. The company expects the acquisition to be accretive in Q4. Comment! [M&A, Healthcare]
Tuesday, March 6, 2012, 4:15 PM Allos Therapeutics (ALTH): Q4 EPS of -$0.01 beats by $0.08. Revenue of $15.4M (+44.4% Y/Y) in-line. Shares -2.9% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Tuesday, January 31, 2012, 8:20 AM Shares of Allos Therapeutics (ALTH) move up 8.1% premarket on chatter that the firm could be a beneficiary of the decision by Cell Therapeutics (CTIC) to withdraw its NDA with the FDA. Comment! [Healthcare, On the Move]
Monday, January 23, 2012, 3:48 PM Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%. Comment! [Healthcare, On the Move]
Monday, January 23, 2012, 9:53 AM Shares of AMAG Pharmaceuticals (AMG -4.4%) move lower after the firm takes on a downgrade from JPMorgan to Underweight. The ratings move on AMAG is part of a larger sector call that includes VPHM, ACOR, AMGN, and ALTH all getting slashed on valuation. Comment! [On the Move, Healthcare]
Friday, January 20, 2012, 9:15 AM Premarket gainers: INSM +24%. ASIA +16%. SWKS +6%. URRE +6%. MPC +5%. BCS +4%. CTIC +4%. RBS +3%. IBM +3%. SAVE +3%. MSFT +3%.
Losers: ALTH -20%. GOOG -8%. AONE -7%. SQNM -6%. HTGC -6%. COF -6%. PH -5%. ZIOP -5%. MMLP -5%. BWP -4%. CX -4%. CUK -4%. ARCC -4%. CCL -3%. NVS -3%. MT -3%. Comment! [On the Move]
Friday, January 20, 2012, 8:42 AM Allos Therapeutics (ALTH) -19.3% premarket after receiving a negative opinion from European regulators on its Folotyn treatment for patients with peripheral T-cell lymphoma. The company says it plans to submit a request for re-examination of the opinion within two weeks. Comment! [Healthcare, On the Move]
Friday, October 21, 2011, 9:59 AM Allos Therapeutics (ALTH -6.2%) and AMAG Pharmaceuticals (AMAG +4.5%) terminate their merger agreement after AMAG shareholders fail to approve the issuance of shares of common stock to ALTH stockholders. 1 Comment [Healthcare, M&A]
Monday, October 10, 2011, 2:44 PM Allos Therapeutics (ALTH -18%) takes a hit after it says an anonymous bidder has withdrawn a takeover offer of $2.20 a share. The company says it will continue working toward with AMAG Pharmaceuticals (AMAG +2.3%). 1 Comment [Healthcare, On the Move]
Wednesday, September 21, 2011, 9:33 AM Allos Therapeutics (ALTH) is up 11%, and AMAG Pharmaceuticals (AMAG) up 2%, after Allos discloses it's received a $2.20/share offer to acquire the company, though it warns its board has not recommended the proposal. AMAG's planned buyout of Allos has been threatened by shareholder opposition following MSMB Capital's offer for AMAG. Comment! [Healthcare, On the Move, M&A]
Wednesday, September 21, 2011, 9:15 AM Premarket gainers: OREX +66%. ALTH +15%. ARNA +9%. ORCL +5%. ADBE +5%. HLS +5%. CS +4%. MCP +4%. ALU +3%. YRCW +3%.
Losers: WLT -13%. ANR -10%. PCX -5%. ACI -5%. NUVA -4%. BTU -4%. -3%. TCK -3%. Comment! [On the Move]
Wednesday, September 7, 2011, 8:54 AM The proposed $686M merger between Amag Pharmaceuticals (AMAG) and Allos Therapeutics (ALTH) could be scuttled after two large shareholders of AMAG threaten to vote against the transaction. Reports say the investors are evaluating if a management shakeup or supporting a tender offer from MSMB Capital might be better options. AMAG +8.1% premarket. Comment! [On the Move, Healthcare, M&A]